期刊文献+

HPLC测定人体血浆中盐酸格拉司琼 被引量:6

Determination of Granisetron Hydrochloride in Human Plasma by HPLC
暂未订购
导出
摘要 目的建立RP—HPLC-荧光色谱法测定人血浆中盐酸格拉司琼的含量。方法以20名健康男性志愿者为研究对象,采用交叉给药方案,分别单剂量口服2mg的试验制剂和参比制剂。采取液-液萃取法处理血浆样品,色谱柱为Diamonsil C18(150mm×4.6mm,5μm),流动相为甲醇-0.5%三乙胺水溶液(pH4.0)(46:54),激发和发射波长分别为305nm和360nm,流速为1.0mL·min^-1。结果盐酸格拉司琼在0.078~20.08ng·mL^-1线性关系良好(r=0.9994),最低检测限为1.95×10^2ng·mL^-1,日内RSD〈1.9%,日间RSD〈3.3%,平均提取回收率为85.7%,平均方法回收率为100.0%。结论该方法快速、准确,适用于盐酸格拉司琼的临床药动学研究和血药浓度监测。 OBJECTIVE A simple RP-HPLC method with fluorescence detection was established for the determination of granisetron hydrochloride in human plasma. METHODS Twenty healthy volunteers were given a single oral dose of granisetron hydrochloride dispersible tablet or tablet (control) in a randomized crossover study. The samples were extracted by liquid-liquid extraction. A Diamonsil C18column was used with the mobile phase of methanol-0.5% triethylamine( pH 4.0 ) (46:54 ) and the flow rate was 1.0 mL ·min^ -1. The excitation and emission wavelengths of fluorescence detection were 305 nm and 360 nm, respectively. RESULTS The calibration curve was linear in the concentration range of 0. 078 - 20.08 ng · mL^-1 and the detective limit of concentration was 1.95 × 10^-2 ng · mL^-1. The intra-day RSD and inter-day RSD were less than 1.9% and 3.3% ,respectively. The average extraction recovery was 85.7%. The average recovery of the method was 100.0%. CONCLUSION The method is sensitive and accurate for the determination of granisetron hydrochloride in human plasma.
出处 《中国现代应用药学》 CAS CSCD 北大核心 2008年第4期323-325,共3页 Chinese Journal of Modern Applied Pharmacy
关键词 盐酸格拉司琼 高效液相色谱 granisetron hydrochloride HPLC
  • 相关文献

参考文献5

  • 1LEE C R, PLOSKER L, Mc Tavashi D, et al. A review of its Pharmacodynamic and Pharmacokinetic properties, and therapeutic potentional as an antiamitic [ J]. Drugs, 1993,46 (5) : 925-943.
  • 2DIDIER C,FRANCOISE B, LUCIEN A,et al. Evaluation of the bioequivalence of tablet and capsule formulations granisetron in pations undergoing cytotoxic chemotherapy for malignant disease [ J ]. J Pharm Sci, 1993,82 ( 12 ) : 1281-1284.
  • 3FREDERIC P, FRANCOISE B, PASCAL M, et al. High- performance liquid chromatographic determination of granisetron in human plasma [ J]. J Chromatogr B, 1996,675:99-105.
  • 4章杰兵,周国华,古卓良.国产和进口盐酸格拉司琼片人体药物动力学和相对生物利用度[J].中国临床药学杂志,2000,9(6):355-357. 被引量:6
  • 5熊玉卿,傅颖君,傅军,姜敏,戴群.盐酸格拉司琼分散片生物等效性评价[J].中国新药杂志,2000,9(7):468-470. 被引量:4

二级参考文献5

  • 1[1]Sanger GJ, Nelson DR. Selective and functional 5-HT3 receptor antagonism by BRL 43694 (granisetron). Eur J Pharmacol, 1989, 159:113
  • 2[2]Van Wijanaarden L, Tulp MTM, Soudijn W. The concept of selectivity in 5-HT receptor research. Eur J Pharmacol, 1990, 188:301
  • 3[3]Cupissol D, Bressolle F, Adenis L, et al. Evaluation of the bioequivalence of table and capsule formulations of granisetron in patients undergoing cytotoxic chemotherapy for malignant disease. J Pharm Sci, 1993, 82(12):1281
  • 4 Lee CR,PloskerL, McTavish D, et al. A review of its pharmacodynamic and pharmacokinetic properties, andtherapeutic potential as an antiemetic[J]. Drugs, 1993, 46(5)∶925
  • 5 Boppana VK. Simultaneous determination of granisetion and 7-hydroxymetabolite in human plasma by reversed-phase high-performance liquid chromatographyutilizing fluoresence and electrochemical detection[J].J Chromatogr A, 1995, 692(1-2)∶195 [3] Allen A, Asgill CC, Pierce DM, et al. Pharmacokinetics and tolerability ofascending vintravenous doses of granisetron, a novel 5-HT3 antagonist, inhealthy human subjects[J].J Clin Pharmacol, 1994, 46(2)∶159 收稿:1999-11-23

共引文献6

同被引文献519

引证文献6

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部